Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Non-cash Items (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Non-cash Items data on record, last reported at $11.1 million in Q4 2025.

  • For Q4 2025, Non-cash Items rose 273.99% year-over-year to $11.1 million; the TTM value through Dec 2025 reached $11.1 million, up 273.99%, while the annual FY2025 figure was $11.1 million, 273.99% up from the prior year.
  • Non-cash Items reached $11.1 million in Q4 2025 per ACRS's latest filing, up from $2.2 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $38.2 million in Q2 2023 and bottomed at $13000.0 in Q3 2024.
  • Average Non-cash Items over 5 years is $12.4 million, with a median of $13.9 million recorded in 2021.
  • Peak YoY movement for Non-cash Items: plummeted 99.91% in 2023, then surged 21100.0% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $13.7 million in 2021, then grew by 11.51% to $15.3 million in 2022, then tumbled by 99.91% to $14000.0 in 2023, then soared by 21100.0% to $3.0 million in 2024, then soared by 273.99% to $11.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $11.1 million in Q4 2025, $2.2 million in Q3 2025, and $14.0 million in Q2 2025.